Roseburia intestinalis: A possible target for vascular calcification

Area of Science:

• Microbiology
• Metabolomics
• Cardiovascular Science

Background:

• Vascular calcification (VC) is prevalent in atherosclerosis, hypertension, diabetes, and chronic kidney disease, contributing to cardiovascular mortality.
• The gut microbiome's role in various disorders, including cardiovascular and metabolic diseases, is increasingly recognized.
• Roseburia intestinalis, a next-generation probiotic, shows potential in mitigating systemic inflammation and treating related disorders.

Purpose of the Study:

• To explore the mechanism by which Roseburia intestinalis's metabolite, butyrate, inhibits vascular calcification (VC).
• To identify butyrate as a potential therapeutic target for VC treatment.
• To investigate methods for enhancing butyrate's therapeutic effects on VC.

Main Methods:

• Review of current literature on gut microbiome, metabolomics, and vascular calcification.
• Analysis of butyrate's molecular targets and metabolic pathways.
• Exploration of Roseburia intestinalis and its metabolite, butyrate.

Main Results:

• Butyrate, a primary metabolite of Roseburia intestinalis, interacts with receptors (GPR43, GPR41, GPR109a) and transporters (MCT1, SMCT1).
• Butyrate modulates gene expression via HDACs, PPARγ, and Nrf2, influencing energy metabolism.
• Butyrate affects circulating metabolites (AGEs, LPS, BHB), impacting systemic processes relevant to VC.

Conclusions:

• Butyrate produced by Roseburia intestinalis demonstrates a potential mechanism for inhibiting vascular calcification.
• Butyrate's multifaceted actions suggest it as a promising therapeutic target for VC.
• Further research into enhancing butyrate's effects could lead to novel VC treatments.